Inactive Instrument

VG Life Sciences Inc. Stock Other OTC

Equities

VGLS

US91822T1016

Biotechnology & Medical Research

Financials (USD)

Sales 2013	-	Sales 2014	-	Capitalization	2.23M
Net income 2013	-7M	Net income 2014	-6M	EV / Sales 2013	-
Net Debt 2013	2.49M	Net Debt 2014	3.83M	EV / Sales 2014	-
P/E ratio 2013	-0.25 x	P/E ratio 2014	-0.31 x	Employees	-
Yield 2013 *	-	Yield 2014	-	Free-Float	100%

More Fundamentals * Assessed data

Chart VG Life Sciences Inc.

Duration

Period

Style

Dynamic Chart

Latest news about VG Life Sciences Inc.

Feelux Co., Ltd completed the acquisition of 23.09% stake in VG Life Sciences Inc. from Alpha Holdings, Inc. and others for KRW 17.3 billion.	18-11-22	CI
Alpha Holdings, Inc. cancelled an additional stake of 12.49% in VG Life Sciences Inc from TJU Asset Management, LLC and Penn Life Science, LLC.	17-10-11	CI
VG Life Sciences Inc. announced that it has received $5.226 million in funding from Alpha Holdings, Inc.	16-10-30	CI
Alpha Holdings, Inc. agreed to acquire an additional stake of 12.49% in VG Life Sciences Inc from TJU Asset Management, LLC and Penn Life Science, LLC for KRW 4.7 billion.	16-10-11	CI
VG Life Sciences Inc. announced that it expects to receive $5.23 million in funding from Alpha Holdings, Inc.	16-09-11	CI
VG Life Sciences Inc. Announces Management Changes, Effective April 1, 2016	16-03-30	CI
VG Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	15-04-14	CI
VG Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	15-02-10	CI
VG Life Sciences Inc. Progress Update Phase I Cancer Study	14-09-04	CI
VG Life Sciences Inc. Reports Clinical Outcomes in Phase I Cancer Study	14-03-14	CI
VG Life Sciences, Inc. Announces Update on Phase I Cancer Study	13-12-13	CI
VG Life Sciences Inc. Closes $2,235,000 from Private Fund	13-10-02	CI
VG Life Sciences Inc. announced that it has received $2.24 million in funding.	13-10-02	CI
Vg Life Sciences, Inc. Names John Tynan as Interim CEO & President	13-07-18	CI
VG Life Sciences Inc. Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial	13-04-04	CI

More news

Press releases VG Life Sciences Inc.

VG Life Sciences : Attorney Letter with Respect to Current Information	22-07-11	PU
VG Life Sciences : Attorney Letter with Respect to Current Information	22-06-09	PU
VG Life Sciences : Annual Report	22-03-31	PU
VG Life Sciences Announces Issuance of Patent Covering Treatment of Inflammatory Bowel Disease with Clip-Inducing Agent	15-01-29	GL
VGLS Q4 2014 Shareholder Update Letter	15-01-14	GL

More press releases

Managers and Directors - VG Life Sciences Inc.

Managers	Title	Age	Since
Paul Stricklandd BRD	Director/Board Member	48	16-12-31
Ana Gois IRC	Investor Relations Contact	-	-
M. Karen Newell-Rogers PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Paul Stricklandd BRD	Director/Board Member	48	16-12-31

More insiders

Company Profile

VG Life Sciences Inc. is engaged in research and development of therapeutic and diagnostic pharmaceutical and medical products. The Company has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+0.73%	43.84B
MODERNA, INC.	+5.52%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.21%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.11%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.42%	12.29B
MEDPACE HOLDINGS, INC.	+26.52%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.15B

Other Biotechnology & Medical Research